ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The funding was led by Cowin Capital, with participation from the National Innovation Center for Advanced Medical Devices. The proceeds will be used to accelerate the company’s research and development (R&D) pipeline, industrialization efforts, and marketing investments.
Platform and Market Potential
Founded in 2022, ConceMed has established itself as a leader in the digestive endoscope market with China’s first integrated soft endoscope platform. The company’s novel gastroscope and enteroscopy products are designed to enhance diagnostic and therapeutic capabilities in gastrointestinal procedures. The soft endoscope market is projected to grow significantly, reaching an estimated RMB 8.12 billion (USD 1.2 billion) by 2025 and RMB 11 billion (USD 1.64 billion) by 2030. This growth trajectory underscores the significant market potential for ConceMed’s innovative products.
Future Outlook
The successful completion of the Pre-Series A financing round positions ConceMed to capitalize on the growing demand for advanced digestive endoscopes. With strong financial backing and a robust R&D pipeline, the company is poised to expand its market presence and drive innovation in the field of gastrointestinal diagnostics and treatment. ConceMed’s integrated platform and novel products are expected to play a key role in shaping the future of the soft endoscope market.-Fineline Info & Tech
